Home
overview

SMi is delighted to announce the 13th annual ADMET conference returning to London on the 9th - 10th July 2018.

Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times.

The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022*. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage.


*Source: http://bit.ly/2hMJcgU


Join our expert speaker panel at the 13th annual ADMET conference to ensure you do not miss out on the latest developments!

Presenting new technologies, specific case studies and PK modelling strategies in the areas of DMPK, PBPK, PKPD, in vitro / ex vivo / in vivo / in silico, biologics, transporters, hazard and safety assessments, ADMET modelling, and many more.

 



 

The 13th annual ADMET conference will cover new developments in all areas of the ADMET sector, from the evaluation of novel PBPK modelling softwares to the validation of humanised mice models.

 

Join us this year in July to hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including:

ADME/PK Optimisation for Drug Design and Discovery
Physiochemical Assessments
In Vitro to Human In Vivo Translation
Physiologically Based PK Modeling
DMPK, PBPK, PKPD
Pre-/Clinical Toxicity
Biopharmaceuticals
Accurate First-in-Human Dose Predictions
Transporters, Bioavailability, Formulation
Drug Delivery
Metabolism Studies
Drug-Drug Interactions
In vivo / in vitro / in silico
Hazard and Safety Assessment
Predictive Toxicology
Preclinical Pharmacology Testing
 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

9:10 Novel Technologies and Computational Tools in Discovery Toxicology: Opportunities and Challenges

Eric Blomme

Eric Blomme, Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
View Bio

• Driving nonclinical safety-related attrition to sustainable levels
• Technologies to define target-related safety
• Computational prediction of off-target interactions
• Opportunistic use of in vitro models to tackle complex toxicity issues
 

9:50 How advanced are our in vitro discovery toxicology assays for predicting DILI risks

Timothy Schulz-Utermoehl

Timothy Schulz-Utermoehl, Director of DMPK, Sygnature Discovery Ltd
View Bio

• Generating an understanding as to when predictive in vitro screening should be performed in Discovery
• Use of case studies to qualify the predictability of the available in vitro assays
• Defining if potential metabolites should be screened alongside the active drug
 

10:30 Morning Coffee

11:00 Understanding the correlation between drug exposure, efficacy and toxicity in a transporter mediated drug-drug interaction

Kunal Taskar

Kunal Taskar, Senior Investigator & Associate Fellow, GSK
View Bio

• Transporter mediated drug-drug interactions (tDDI) and clinical impact
• Effect on drug  efficacy in a tDDI
• Effect on drug toxicity in a tDDI
• Simultaneous correlation of drug exposure in tDDI with efficacy and toxicity
 

11:40 Spotlight: The importance of ADMET in medicines regulation: First in human studies and dose-exposure-response analyses

Justin Pittaway-Hay

Justin Pittaway-Hay, Pharmacokinetics Assessor, MHRA

• Regulations concerning FIH studies and PBPK modelling and simulation: ADMET considerations
• Importance of demonstrating dose-exposure response relationships
• Extrapolation of PK and role in paediatric populations

 

12:20 Networking Lunch

13:20 Use of early dose prediction and ADMET properties to guide chemical design

Nenad Manevski

Nenad Manevski, DMPK Design Lead, Senior Scientist in Biotransformation and Enzymology, UCB
View Bio

• Early dose predictions can be used to guide chemical design and prioritise efforts.  
• Multi-parameter design improves quality of drug-like properties.
• Metabolic stability, permeability, and solubility are linked with toxicological outcomes. 
 

14:00 Hypothesis testing with PBPK to understand if solubility limits in vivo absorption

Sheila Annie Peters

Sheila Annie Peters, Head, Translational Quantitative Pharmacology, Merck Serono
View Bio

• Solubility and dissolution of a drug measured in vitro are often used in PBPK models to understand their in vivo relevance, to assess the need for formulation development, as well as to estimate the effects of food and acid reducing agents (ARA) on the absorption.
• When clinical data following PO administration becomes available, in the absence of IV PK, verification of PBPK model, especially when confounded by gut metabolism and efflux, is difficult to achieve due to parameter non-identifiability.
• This presentation will talk about hypothesis testing with PBPK and how we can employ it for overcoming parameter non-identifiability in order to better predict food and ARA effects on the absorption of an API or a formulation.
 

14:40 Afternoon Tea

15:10 The use of precision-cut lung slicing model to study pulmonary disposition of a drug

Yildiz Yilmaz

Yildiz Yilmaz, Pharmacokineticist, ADME, Biotransformation, Novartis AG

• Assessment of the pulmonary CYP1A1 metabolism of mavoglurant in rat
• Functional assessment of rat pulmonary Flavin-containing Monooxygenase activity
• Optimization of the precision cut lung slices (PCLS) as a useful tool for assessment of the pulmonary drug disposition in rat and human
 

15:50 Use of Quantitative Approaches in Drug Development: An Oncology Perspective

Pau Aceves

Pau Aceves, Associate Director, Certara Strategic Counselling
View Bio

• The use of Quantitative Clinical Pharmacology approaches in oncology are an essential part of the development of new drugs in oncology.
• Technological advances are increasingly making feasible the conduct of Phase I studies in oncology patients, which were previously considered impossible i.e. human ADME in oncology patients
• The use of techniques such as Population PK/PD as well as PBPK modelling can be used to supplement insights where knowledge gaps exist
• The timely execution of the right clinical studies combined with the right PKPD modelling tools ensures the approvability of new cancer therapies
• A literature review of the state-of-the-art in QCP clinical development strategies will be presented, and a case study focusing on challenges of the human ADME in cancer patients and the streamlining of an oncology program by using PBPK will also be presented.
 

16:30 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Eric Blomme

Eric Blomme, Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
View Bio

9:10 Human PK and dose predictions for compounds with challenging physiochemical profiles

Peter Littlewood

Peter Littlewood, Director DMPK, Vertex Pharmaceuticals


• Understanding the physicochemical properties of a compound:  solubility, stability, form definition, solid-state properties, partition coefficient and ionization constants
• The optimization of these properties is fundamental to the drug discovery process, mainly due to their influence on absorption and distribution in vivo.
• Alterations of physicochemical properties such as molecular weight, log d, polar surface area or pKa may influence the absorption, distribution, metabolism or excretion (ADME) of a chemical series in a chemotype-dependent manner
• Application of mechanistic approaches to solving ADME issues provides insight as to why a change in properties causes a desired outcome in some cases, while leading to poorer outcomes in others.
 

9:50 Biotransformation of biotherapeutics - Impact on candidate selection

Filipe Lopes

Filipe Lopes, DMPK Laboratory Head, Roche
View Bio

• Metabolism of Small-Molecule Drugs vs Biotherapeutics
• Impact of Protein Biotherapeutics Biotransformation on BIoanalysis
• Workflows for Studying Protein Biotherapeutics
• The future of the field
 

10:30 Morning Coffee

11:00 Impact of target interactions on small-molecule drug disposition: an overlooked area?

Robert van Waterschoot

Robert van Waterschoot, Head of Pharmacokinetics, Dynamics & Metabolism PDM Leaders, Roche Pharmaceuticals
View Bio

• Relevance of target-mediated drug disposition (TMDD) for small molecules
• Impact of TMDD on pharmacokinetic parameters
• Consequences of TMDD in human microsoding studies
• When and how to evaluate TMDD for small molecules?
 

11:40 Advances in models for the prediction of human drug metabolism

Ian Wilson

Ian Wilson, Chair, Drug Metabolism and Molecular Toxicology, Imperial College
View Bio

• Avoiding problems in drug development requires good methods for the prediction of drug metabolism/toxicology.
• Accurate models that to predict liver-based metabolism in humans human are needed
•  Liver humanized models in rodents based on genetic modification or “chimeric” livers show some promise in this area
•  The pros and cons of the use of each type of systems will be described and illustrated with examples
 

12:20 Networking Lunch

13:20 Distribution, Metabolism and Excretion - A case study on hepatocyte transporters at Genentech

Laurent Salphati

Laurent Salphati, Principal Scientist, Genentech, Inc.
View Bio

• In vitro and In Vivo techniques used to predict pharmacokinetic profile of a compound at a pre-clinical stage.
• Explore the use of an assay developed to measure the disposition of a compound from hepatocytes into the blood.
• Transport systems include transporters for amino acids, monocarboxylic acids, organic cations, hexoses, nucleosides, and peptides and most of these function in the direction of (mainly) efflux from liver to blood.
 

14:00 intracellular pharmacokinetics: emerging opportunities for tailoring project support

Andreas Reichel

Andreas Reichel, VP, Head Research Pharmacokinetics, Bayer
View Bio

• With significant progress in delivery technologies, peptides and peptidomimetics are receiving increasing attention as potential therapeutics for intracellular applications
• Analyses of the intracellular behaviour of peptides are a challenge making knowledge on the intracellular PK of peptides limited
• Defining structure–activity relationship of peptides with respect to intracellular residence time and proteolytic breakdown is complex
• Useful in in vitro efficacy, safety and toxicology testing and a potential link to the optimisation of in-vivo assessments and predictive pharmacology
 

14:40 Afternoon Tea

15:10 Towards a fully PBPK compliant ADME-MOC

Reyk Horland

Reyk Horland, Head of Business Development, TissUse GmbH

•             Introduction to Multi-Organ-on-chip (MOC) solutions
•             The 4-Organ-Chip: A first proof of concept for ADME-studies
•             A PBPK modelling approach for Multi-Organ-Chips
•             Current and future applications
 

15:50 Chairman’s Closing Remarks and Close of Day Two

Eric Blomme

Eric Blomme, Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
View Bio

+

FEATURED SPEAKERS

Eric Blomme

Eric Blomme

Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
Ian Wilson

Ian Wilson

Chair, Drug Metabolism and Molecular Toxicology, Imperial College
Kunal Taskar

Kunal Taskar

Senior Investigator & Associate Fellow, GSK
Nenad Manevski

Nenad Manevski

DMPK Design Lead, Senior Scientist in Biotransformation and Enzymology, UCB
Pau Aceves

Pau Aceves

Associate Director, Certara Strategic Counselling
Robert van Waterschoot

Robert van Waterschoot

Head of Pharmacokinetics, Dynamics & Metabolism PDM Leaders, Roche Pharmaceuticals
Sheila Annie Peters

Sheila Annie Peters

Head, Translational Quantitative Pharmacology, Merck Serono
Timothy Schulz-Utermoehl

Timothy Schulz-Utermoehl

Director of DMPK, Sygnature Discovery Ltd

Andreas Reichel

VP, Head Research Pharmacokinetics, Bayer
Andreas Reichel

Andreas is Vice President and Head of Research Pharmacokinetics at Bayer Pharmaceuticals Research and Development. His department operates at two sites, Berlin and Wuppertal, and is responsible for the DMPK support of drug discovery projects of all therapeutic areas of Bayer Pharma including cardiology, oncology, and gynaecological therapy.
Andreas received his PhD in Cell Biology from the University of Leipzig in 1994 studying the regulation of nutrient transport processes at the blood-brain barrier (BBB) in vivo under the supervision of Prof. Armin Ermisch.
Between 1994 and 1997 he was working in the laboratories of Profs. Joan Abbott and David Begley, King’s College London, where he became interested in in vitro models of the BBB. Funded by several pharmaceutical companies he started working on approaches to assess and predict the CNS penetration of drugs. In 1997, Andreas joined Discovery DMPK at Hoffmann-La Roche, Basel, where he expanded his area of expertise to intestinal and hepatic transport processes and their relevance to drug absorption, drug disposition and drug-induced liver toxicity. In 2000, Andreas joined Schering AG in Berlin where he helped setting up and soon became to lead the department of Research Pharmacokinetics with responsibility for in vitro ADME assays and in vivo PK studies as well as all PK and PK/PD modelling activities to predict the PK and the therapeutic dose in human. After the merger with Bayer in 2006, both RPK departments were combined under his leadership supporting all drug discovery projects of Bayer’s Pharma portfolio starting from lead discovery, through to lead optimisation and candidate selection and profiling, and beyond for both small molecules and biologics.
 

Eric Blomme

Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
Eric Blomme

Eric Blomme is Vice President, Global Preclinical Safety at Abbvie Inc. Eric has held several positions at Abbott/AbbVie, including Director Investigative Toxicology and Pathology, Director Integrated Pharmacology, and Project Leader Discovery Advanced Technologies. Prior to joining AbbVie, he worked at Pharmacia and Searle.
Eric attended the University of Lyon (Doctor in Veterinary Medicine), McGill University (Business School), Cornell University (Residency in Pathology) and The Ohio State University (PhD). Eric is Diplomate of the American College of Veterinary Pathologists. He has published over 70 peer-reviewed manuscripts, multiple editorials, several book chapters, and a book.
 

Filipe Lopes

DMPK Laboratory Head, Roche
Filipe Lopes

After completing a PhD in Analytical Chemistry at King’s College London 2012, Filipe initiated his professional career at Novartis NIBR, in the UK where he helped setting-up a new mass spectrometry based lab to support enzymology studies within respiratory diseases. Decided to expand his skill set in DMPK, and in particular Drug Metablism, gained experience as a Biotransformation and Senior DMPK Scientist at Pharmaron and Evotec and in 2015 joined Roche pRED Basel as Laboratory Head in Drug Metabolism. Currently, Filipe is involved in projects that cover a wide variety of modalities (Small and Large molecules) across various therapeutic areas, including Oncology and Neurosciences.

Ian Wilson

Chair, Drug Metabolism and Molecular Toxicology, Imperial College
Ian Wilson

Ian D Wilson worked in the pharmaceutical industry for 36 years, most recently as a senior Principal Scientist in the Dept. of Drug Metabolism and Pharmacokinetics at the AstraZeneca research site at Alderley Park in Cheshire, in the UK. In 2012 he moved to Imperial College (London) where he is Professor of Drug metabolism and Molecular Toxicology in the Dept of Surgery and cancer. His research is centred on metabolic phenotyping, drug metabolism, the microbiome and drug bioanalysis, with a particular emphasis on xenobiotic metabolism as a source of adverse drug reactions.

Justin Pittaway-Hay

Pharmacokinetics Assessor, MHRA
Justin Pittaway-Hay

Kunal Taskar

Senior Investigator & Associate Fellow, GSK
Kunal Taskar

Kunal S. Taskar, Ph.D.
GlaxoSmithKline

Biosketch

Kunal Taskar, Ph.D., is currently working as an Associate GSK Fellow and Scientific Leader at GlaxoSmithKline, U.K. in Mechanistic Safety and Disposition, IVIVT R&D department. He is the transporter expert at the GSK UK site and consults on drug transporter related project questions from early drug discovery to post-marketing drug development. His past experience includes working as a drug transporter expert in the DMPK Pharmaceutical Candidate Optimization department at Biocon Bristol-Myers Squibb Research and Development. Kunal completed his doctorate and postdoctoral research at Texas Tech University Health Sciences department, USA, in Quentin Smith’s lab with research focused on drug delivery to central nervous system and role of transporters in drug delivery across the blood-brain barrier (BBB).

Kunal’s experience and research focus include: drug-drug interaction predictions using PBPK models and mechanistic understanding of the clinically occurring drug–drug interactions; transporter mediated drug delivery and intracellular drug concentrations, especially the role of uptake and efflux transporters in drug pharmacokinetics-pharmacodynamics and disease and toxicology; novel transporters and role in drug disposition (research on critical role of novel transporters at the BBB); improvising current transporter assays and models for drug transporter studies and clinical predictions; and use of endogenous probes for drug mediated transporter modulations.

Kunal is a member of American Association of Pharmaceutical Scientists (AAPS) and the International Brain Barriers Society. Kunal is also a member of the Predictive Safety Testing Consortium Hepatox-BSEP working group and member of the International Transporter Consortium Whitepaper 2018 effort focused on bile salt export pump transporter.
 

Laurent Salphati

Principal Scientist, Genentech, Inc.
Laurent Salphati

Dr. Laurent Salphati is currently Principal Scientist in the Drug Metabolism and
Pharmacokinetics department at Genentech, Inc. He heads the Drug Transporter
group and has been supporting and leading immunology and oncology project teams
from preclinical discovery to late stage clinical development. He received his Pharm.D.
from the University of Paris XI, France, and conducted his Ph.D research,
investigating the complementary roles of P-glycoprotein and CYP3A in drug
absorption and disposition, at the University of California, San Francisco under the
guidance of Dr. Leslie Z. Benet. His research interests include the pharmacokinetics
and pharmacodynamics of drugs, and the role of drug transporters in drug
absorption and disposition.
 

Nenad Manevski

DMPK Design Lead, Senior Scientist in Biotransformation and Enzymology, UCB
Nenad Manevski

Nenad Manevski is the DMPK Design Lead within Development Sciences at UCB Pharma in Slough, UK. Nenad is part of multi-disciplinary drug design team, closely working with medicinal chemists, toxicologists, and pharmacokineticists to increase drug-likeness of compounds in discovery process. His work strongly relies on application of in silico tools, in vitro – in vivo extrapolations, and early-dose predictions to set priorities and achieve multi-parametric optimisation.


Pharmacist by training, Nenad received this PhD in Enzymology & Medicinal Chemistry from University of Helsinki, Finland, and did his Postdoc within Biotransformation team of Novartis Institutes for Biomedical Research in Basel, Switzerland. His particular research interests are extrahepatic drug metabolism, aldehyde oxidase, drug design, and applications of early dose predictions. Nenad has authored 10 peer-reviewed publications and presented his work at numerous international meetings in the ADMET field.
 

Pau Aceves

Associate Director, Certara Strategic Counselling
Pau Aceves


Pau Aceves joined Certara Strategic Consulting in February 2017. Pharmacist by training, and with previous work experience in diverse aspects of the Pharmacy practice—including Community, Clinical and Production Pharmacy—Pau focused his professional career path in the field of Quantitative Clinical Pharmacology (QCP) and PK/PD Modeling & Simulation, since 2006.


Pau Aceves holds a Master’s Degree in PK/PD Modeling & Simulation from the University of Manchester in the UK. His MSc project was on an Exploratory Quantitaitve Systems Pharmacology Model (QSP) of the Squalene Synthase Inhibitor Lapaquistat Acetate.


In addition to having worked on QCP-type studies (ie, food effect, bioavailability, DDIs), Pau also has a wide range of experience on other modalities, including: First-in-human (SAD/MAD), Proof-of-mechanism (PoM), Proof-of-concept (PoC), Positron Emission Tomography (PET), and complex combination (or umbrella-type) protocols; as well as experience interacting with regulatory agencies (FDA, EMEA) at various stages of drug development.


He has a total of 11 years of QCP experience in the design, analysis and reporting of studies in a wide range of therapeutic areas across all phases of drug development. Pau always enjoys devising innovative strategies to streamline and maximize the value of clinical development programmes by combining efficient clinical strategies with fit-for-purpose PK/PD analysis methods, eg, Population PK/PD, Physiologically-based Pharmacokinetic modeling, and Quantitative Systems Pharmacology approaches.
 

Peter Littlewood

Director DMPK, Vertex Pharmaceuticals
Peter Littlewood

Reyk Horland

Head of Business Development, TissUse GmbH
Reyk Horland

Robert van Waterschoot

Head of Pharmacokinetics, Dynamics & Metabolism PDM Leaders, Roche Pharmaceuticals
Robert van Waterschoot

Dr. Robert A.B. van Waterschoot is currently a Group Head of DMPK/PD Project Leaders at the Roche Innovation Centers in Basel, Copenhagen and New York.

Prior to his career at Roche, he acquired experience in the DMPK departments of Merck (USA), Solvay Pharmaceuticals (the Netherlands) and Abbott/AbbVie (Germany).

Dr. Van Waterschoot has an MSc degree in Molecular Toxicology from the VU University Amsterdam and a PhD degree in Pharmacokinetics & Drug Toxicity from the Dutch Cancer Institute in Amsterdam. He has more then 20 peer-reviewed publications in the field of DMPK.
 

Sheila Annie Peters

Head, Translational Quantitative Pharmacology, Merck Serono
Sheila Annie Peters

Dr. Sheila Annie Peters heads the Translational Quantitative Pharmacology group at Merck Darmstadt. Her areas of expertise in DMPK include Physiologically-based pharmacokinetic (PBPK)-Phamacodynamics (PD) modeling, and PK/PD and drug-drug interactions. Prior to this, she worked at AstraZeneca, Mölndal, where she developed a generic whole-body PBPK model in MATLAB® which she used to support several drug discovery and early development projects across different R&D sites with innovative approaches to identifying potential limitations to drug disposition. She successfully implemented Model-based drug discovery (MBDDx) strategy in Respiratory Inflammation and Autoimmunity iMed through cross-functional collaboration. She won the 2013 IMED (Innovative Medicines) Science Award at AstraZeneca for the “Design and Development of LungSim Simulation tool for Inhalation PK Modelling”. She has published several papers in high impact journals as well as a book on PBPK. As part of the IQ Consortium, she co-authored a White Paper on PBPK along with other experts in industry and continues to work with them on various topics of interest in PBPK.

Timothy Schulz-Utermoehl

Director of DMPK, Sygnature Discovery Ltd
Timothy Schulz-Utermoehl

Dr Schulz-Utermoehl has over 19 years experience in the pharmaceutical industry, spanning early and late-stage discovery research and preclinical development. He has held senior roles at Merck, AstraZeneca and Shire and is currently the Director of DMPK & Physical Sciences at Sygnature Discovery. In parallel to his leadership role at Sygnature Discovery, he is also Vice President of Preclinical Development at Chronos Therapeutics and a Co-founder and NED of Belfry Therapeutics.

Dr Schulz-Utermoehl carried out 2 years of post-doctoral research at Novo Nordisk A/S, Denmark and holds a PhD in Biochemistry from Imperial College, a MSc in Toxicology from the Royal Postgraduate Medical School, University of London and a BSc (Hons) in Pharmacology/Physiology from the University of Leeds.
 

Yildiz Yilmaz

Pharmacokineticist, ADME, Biotransformation, Novartis AG
Yildiz Yilmaz

Official Media Partner

Supporters

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Speaker Interview Nenad Manevski, UCB Pharma

Download

Speaker Interview Pau Aceves, Certara Strategic Consulting

Download

ADMET 2018 Conference Speakers

Download

ADMET 2018 Conference Programme

Download

Brochure Download

Download

2017 Presentation - GENETECH

Download

2017 Presentation - Corning Life Science

Download

2017 Presentation - Bayer Pharma Drug Discovery

Download

2017 Presentation - GSK

Download

PAST ATTENDEE LIST

Download

Media Partners


Samedan

Official Media Partner
http://www.samedanltd.com/magazine/13.

International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.


Drug Discovery Today

Official Media Partner
http://www.drugdiscoverytoday.com/

Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


MedChemNet

Official Media Partner
http://www.medchemnet.com/

MedChemNet is a unique platform aiming to promote global collaboration between all members of this field, enabling you to make the right connections. As well as access to further exclusive medicinal chemistry articles, regular drug discovery and development news updates, engaging multimedia content and exclusive features, you can connect with peers and follow opinion leaders, while sharing your own insights through blogs and videos to help further the discussion.


Technology Networks

Official Media Partner
http://go.technologynetworks.com/subscribe-to-newsletters

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Drug Target Review

Official Media Partner
http://www.drugtargetreview.com

Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


pharmanews hq

Official Media Partner
http://http://pharmanewshq.com

MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.

Media Partners


EIN News

Supporters
http://www.einnews.com

EIN News is the world leader in industry focused online news monitoring. Thousands of leading companies, institutions and global professionals from business, industry, and government rely on EIN News as an indispensable resource. Our systems continuously scan the web, indexing news from thousands of worldwide sources. The news you need is then organized by advanced software systems managed by a team of professional news editors. Everything we do is focused on streamlining your news searches and research in order to save you time and money.


GBI

Supporters
http://www.gbihealth.com/

GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


Biocompare

Supporters
http://www.biocompare.com

Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


European Pharmaceutical Review

Supporters
https://www.europeanpharmaceuticalreview.com/

European Pharmaceutical Contractor (EPC) is a quarterly publication dedicated to the international pharmaceutical contract market. Since its establishment in 1997, EPC has provided coverage of technical, strategic and regulatory developments within the industry. The magazine features in-depth opinion-led articles, reviews and interviews, on topics including drug development, outsourcing, pharmacovigilance, partnerships and eClinical management. Read EPC in print, online, or via the Samedan app.


Absave

Supporters
http://www.absave.com

Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


EBR

Supporters
http://www.samedanltd.com

European BioPharmaceutical Review (EBR) provides a dedicated platform of communication and information for the biopharmaceutical market across Europe, North America and the rest of the world. Each quarterly issue, 10,500 copies of the magazine are distributed to our specially-targeted readership with articles on the hottest topics written by eminent commentators from the biotech scene. www.samedanltd.com


CLocate

Supporters
http://www.clocate.com

Clocate.com is a leading international directory for worldwide conferences and exhibitions. Clocate.com is equipped with a unique and comprehensive search that helps you find easily any event in any category or location. Each event includes detailed information, like, description, dates, location, map, prices, link to the official event's website and more...


ASD MEDIA

Supporters
http://www.asd-network.com

Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
  • Be informed on the latest market developments; www.asd-network.com
  • Find the latest business news; www.asd-network.com
  • Find the upcoming events; www.asd-network.com
  • Find companies and organizations; www.asdsource.com
  • Distribute news globally. www.asdwire.com
The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

For more detailed information please contact with: ASD MEDIA
Stefan.koopman@asdmedia.nl


BioPharm Insight

Supporters
http://www.biopharminsight.com

BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.


Swiss Biotech Association

Supporters
http://www.swissbiotech.org/

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


Contract Biotechnology

Supporters
http://www.contract-biotechnology.com

Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com


Gate2Biotech

Supporters
http://www.gate2biotech.com

Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


AntibodyChain

Supporters
http://www.antibodychain.com

The complete and transparent marketplace for your research antibodies, kits, proteins and small molecules. The sophisticated search engine, with more than 800.000 products, transparency in suppliers, easy comparison, the one stop shop for your research antibodies in combination with interesting news and events plus a CMO exchange makes us a full service partner for you.


European Biotechnology Network

Supporters
http://european-biotechnology.net/

The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.


BioChem Adda

Supporters
https://www.biochemadda.com/

BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!


CanBiotech

Supporters
http://www.canbiotech.com

CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


Select Science

Supporters
http://www.selectscience.net/

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


Copybook - Pharmaceutical

Supporters
http://www.copybook.com/pharmaceutical

Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


Biosave

Supporters
http://www.Biosave.com

Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


Farmavita

Supporters
http://www.farmavita.net/

Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.